Shanghai Fengxian focuses on Genetic drug development

54 industry policy experts, entrepreneurs and investors recently gathered in Shanghai Fengxian to discuss the development and leapfrog opportunities of the gene drug industry involving nucleic acid drugs. Fengxian District Party Standing Committee member and Executive Deputy District Head Gu Yaoming said Fengxian, with its positioning as the western gateway of the new area, the urban center of southern Shanghai, and the vibrant new city in the Yangtze River Delta, has continued to strengthen its economic power and renewed its urban and rural landscape, attracting a number of leading enterprises and industry benchmarks to develop and grow in the district.

Jiang Yingqing, Party Secretary and Chairman of Shanghai Hangzhou Bay Economic and Technological Development Area, introduced the achievements made by the development area in building an innovative industrial base for gene drugs, and expressed the vision to further promote high-quality development of the biopharmaceutical industry. Wang Xuezong, Deputy Party Secretary and General Manager of Hangzhou Bay Development Area, said the development area is actively investing in building public experimental platforms and innovation platforms to provide acceleration and empowerment for enterprise development. Participants also included Huai Min, former Executive President and Global R&D President & CMO of Fosun Pharma, who made an in-depth analysis of the "leapfrog catching-up" logic and future development directions for biotechnology based on his own experience. In addition, there were Zhao Yingliang, review expert of the Nucleic Acid Drug Development Group of the National Biopharmaceutical Technology Innovation Center, Luo Jiayong, Chief Pharmaceutical Analyst of GF Securities and other attendees. They conducted in-depth analyses and discussions on the nucleic acid drug industry from different perspectives.